[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373330":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":65,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":26,"eligibilityCriteria":77,"healthyVolunteers":74,"sex":78,"minAge":79,"maxAge":26,"enrollmentInfo":80,"targetDuration":26,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":26,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Miami","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Microsurgical Clipping Treated with Sirolimus","EXPERIMENTAL","Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.",[13,14],"Procedure: Microsurgical clipping","Drug: Sirolimus",{"label":16,"type":10,"description":17,"interventionNames":18},"Endovascular Treatment Treated with Sirolimus","Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.",[19,14],"Procedure: Endovascular treatment",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Microsurgical clipping","Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Endovascular treatment","Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.",[16],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Sirolimus","Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.",[16,9],[37],"Rapamune",[39],{"name":40,"affiliation":5,"role":41},"Robert M Starke, M.D.","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Jayro Toledo, MD","CONTACT","305-243-8044","j.toledo2@med.miami.edu",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Miami","Florida","33136","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-80.19366,25.77427,{"lat":60,"lon":59},[63,64],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},{"name":40,"role":41,"phone":26,"phoneExt":26,"email":26},{"type":41,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Robert Starke","Assistant Professor",[69],{"name":70,"class":71},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100373330","phase-2-effect-of-sirolimus-on-molecular-alterations-in-cerebral-aneurysms-100373330",false,"NCT04141020","Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms","Inclusion Criteria:\n\n1. Undergoing one of the following procedures at Jackson Memorial Hospital:\n\n   * Clipping of an unruptured cerebral artery aneurysm\n   * Endovascular treatment of unruptured cerebral aneurysms (including those receiving coiling)\n2. ≥ 18 years of age\n3. Willing and able to give informed consent\n\nExclusion Criteria:\n\n1\\) Subjects meeting any of the following criteria will be excluded:\n\n* Dissecting, traumatic, or mycotic brain aneurysm.\n* Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.\n* Women who are breastfeeding.\n* Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.\n* Patients with known Human Immunodeficiency Virus (HIV) infection or other known immunodeficiency.\n* Patient with renal or liver failure\n* Interstitial pneumonitis\n* History of lymphoma\n* History of skin cancer\n* Hypersensitivity to sirolimus\n* Severe or unstable concomitant condition disease or chronic condition, which in the opinion of the investigator could affect assessment of the safety or efficacy of study intervention.","ALL","18 Years",{"count":81,"type":82},80,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.",[88],"Cerebral Aneurysm","2026-03-18",{"date":91,"type":92},"2026-03-23","ACTUAL",{"date":94,"type":92},"2021-10-27",{"date":96,"type":82},"2026-11-01",{"name":5,"class":6},1]